Navigating the Psychedelic Renaissance: Emerging Mental Health Therapies and the Pharmacist’s Role
March 27th 2024Psychedelic medicines such as psilocybin, MDMA, ketamine, and LSD have been shown to have a significant impact on conditions such as major depressive disorder, generalized anxiety disorder, and post-traumatic stress disorder in clinical trials.
Read More
Nirmatrelvir/Ritonavir in Patients With Hematologic Malignancies Improves COVID-19 Outcomes
March 27th 2024Early treatment administration with this regimen also promoted a faster decrease in viral load and shorter viral shedding in patients with hematologic diseases who were positive for COVID-19.
Read More
Pharmacy Focus: Policy Edition - Overview of California's Stop Dangerous Pharmacies Act
March 27th 2024Ron Lanton discusses California's Stop Dangerous Pharmacies Act, which aims to address understaffed chain pharmacies and reduce medication errors by implementing new regulations around pharmacy staffing, error reporting, and unsafe working conditions.
Listen
Phase 3 Trial of Pembrolizumab with Olaparib Did Not Meet Endpoints Among Individuals with NSCLC
March 26th 2024Pembrolizumab in combination with chemotherapy followed by maintenance olaparib did not meet its pre-specified statistical criteria of overall survival or progression free survival.
Read More